Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
HM61713 is an inhibitor of mutant EGFR (IC50 = 0.01 µM for EGFRT790M/L858R).1 It is selective for EGFRT790M/L858R over PI3Kα (IC50 = >10 µM). HM61713 is cytotoxic to A549, H1975, and H460 lung and MCF-7 breast cancer cells (IC50s = 4.29, 0.52, 5.29, and 26.9 µM, respectively). It reduces tumor growth in an ETS1-overexpressing doxorubicin-resistant K562 leukemia mouse xenograft model when administered at a dose of 30 mg/kg in combination with doxorubicin.2
WARNING This product is not for human or veterinary use.
1. Design, synthesis, and antitumor activity of olmutinib derivatives containing acrylamide moiety. Molecules 26(10), 3041 (2021).
2. Olmutinib reverses doxorubicin resistance in ETS1-